The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) recently announced an expansion of its Code of Practice. This code regulates company interactions with healthcare professionals, medical institutions, and patient organizations. As a representative of the research-based pharmaceutical industry, IFPMA requires all member companies and member associations to accept and apply this new Code.
“Advancing medical knowledge and improving global public health depend on regular information-sharing interactions between the medical community and pharmaceutical companies. These exchanges ensure patients benefit from the most up-to-date information regarding medicines,” says IFPMA Director General, Eduardo Pisani. “Ensuring that governments, healthcare providers and patients are confident that interactions with our members are conducted to the highest ethical and professional standards is our commitment.”
The Code continues to forbid preapproval promotional activities for pharmaceutical products, company-sponsored entertainment at events, and providing or offering personal gifts to healthcare professionals.
Beyond these interactions, the expanded Code now includes:
- High-level practice principles
- Mandatory training of all member company employees
- A clear distinction between gifts, promotional aids, and items of medical utility
- Continuing medical education guidance
- Terms for the disclosure of clinical trials information
- Directions for filing complaints
“The new Code provides a framework for the industry to act with integrity and build trust, as we work towards improving patient heath,” says IFPMA President David Brennan.
More information about the IFPMA Code of Practice can be found here.
Source: IFPMA.